Ventas, Inc. (NYSE: VTR) is a Real Estate company in the REIT - Healthcare Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 169.75 | EPS (ttm) | 0.55 | Insider Own | 0.55% | Shs Outstand | 486.17M | Perf Week | -0.16% |
| Market Cap | 45.39B | Forward P/E | 92.39 | EPS next Y | 1.01 | Insider Trans | -1.28% | Shs Float | 510.05M | Perf Month | 1.77% |
| Enterprise Value | 58.84B | PEG | 6.79 | EPS next Q | 0.17 | Inst Own | 109.25% | Short Float | 4.85% | Perf Quarter | 7.87% |
| Income | 267.79M | P/S | 7.05 | EPS this Y | 13.17% | Inst Trans | - | Short Ratio | 5.62 | Perf Half Y | 16.93% |
| Sales | 6.44B | P/B | 3.08 | EPS next Y | 65.35% | ROA | 0.90% | Short Interest | 24.74M | Perf YTD | 20.65% |
| Book/sh | - | P/C | 24.56 | EPS next 5Y | 44.92% | ROE | 2.02% | 52W High | 99.78 -8.11% | Perf Year | 36.29% |
| Cash/sh | - | P/FCF | 28.28 | EPS past 3/5Y | - -14.33% | ROIC | 22.32% | 52W Low | 65.19 40.64% | Perf 3Y | 92.57% |
| Dividend Est. | 2.08 (2.27%) | EV/EBITDA | 23.57 | Sales past 3/5Y | 12.21% 8.98% | Gross Margin | -2.58% | Volatility | 2.63% 2.57% | Perf 5Y | 56.17% |
| Dividend TTM | 2.00 (2.18%) | EV/Sales | 9.13 | EPS Y/Y TTM | 184.21% | Oper. Margin | 12.94% | ATR (14) | 2.47 | Perf 10Y | 25.28% |
| Dividend Ex-Date | Jun 30, 2026 | Quick Ratio | 0.27 | Sales Y/Y TTM | 30.83% | Profit Margin | 4.13% | RSI (14) | 50.94 | Recom | 2.50 |
| Dividend Gr. 3/5Y | 2.17% -2.17% | Current Ratio | 0.27 | EPS Q/Q | -83.91% | SMA20 | -1.66% | Beta | 0.72 | Target Price | 97.07 |
| Payout | 348.97% | Debt/Eq | 0.93 | Sales Q/Q | 21.75% | SMA50 | 4.44% | Rel Volume | 0.57 | Prev Close | 93.36 |
| Employees | 542 | LT Debt/Eq | 1.05 | Earnings | Oct 28 | SMA200 | 11.94% | Avg Volume | 3.97M | Price | 91.69 |
| IPO Date | May 05, 1997 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.64% 2.91% | Net Debt/EBITDA | 5.39 | Volume | 2,276,670 | Change | -1.79% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-31-26 | Reiterated | Cantor Fitzgerald | Overweight | $93 → $102 |
| Jul-22-26 | Reiterated | Mizuho | Outperform | $98 → $104 |
| Jul-07-26 | Downgrade | Barclays | Overweight → Equal Weight | $67 → $99 |
| Jun-18-26 | Reiterated | Scotiabank | Sector Perform | $95 → $88 |
| Jun-16-26 | Resumed | Raymond James | Outperform | $78 → $94 |
| Jun-16-26 | Reiterated | Deutsche Bank | Buy | $95 → $100 |
| May-22-26 | Reiterated | Mizuho Securities | Outperform | $61 → $98 |
| May-21-26 | Reiterated | Scotiabank | Sector Perform | $74 → $95 |
| May-19-26 | Reiterated | Goldman Sachs | Sell | $100 → $110 |
| May-07-26 | Reiterated | Keybanc | Overweight | $85 → $95 |
As an S&P 500 company, Ventas operates strategically at the nexus of the dynamic healthcare and real estate industries. We stand as one of the world's foremost Real Estate Investment Trusts (REITs), utilizing financial capital to unlock property value. Our partnerships extend to leading care providers, developers, research and medical institutions, innovators, and healthcare organizations, all of whom benefit from the significant demographic trend of an aging population. For over two decades, Ventas has pursued a steadfast and effective strategy: maintaining a high-quality, diverse portfolio of assets and varied capital streams to skillfully navigate market fluctuations. A dedicated and experienced team collaborates with industry-leading partners to generate consistent, increasing cash flows and superior returns on a strong balance sheet, ultimately enriching Ventas's shareholders. As of September 30, 2020, Ventas either owned outright or managed through unconsolidated joint ventures approximately 1,200 properties.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,442 | 5,834 | 4,924 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 6,609 | 6,178 | 2,827 | — | — | — | — | — | — | |
| Gross Profit | -167 | -344 | 2,097 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 191 | 177 | 163 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | -1,190 | -1,348 | 1,253 | — | — | — | — | — | — | |
| Operating Income | 834 | 827 | 681 | — | — | — | — | — | — | |
| Interest Expense | 770 | 612 | 603 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 164 | 33 | -28 | — | — | — | — | — | — | |
| Net Income Before Taxes | 227 | 247 | 51 | — | — | — | — | — | — | |
| Income Taxes | -49 | -14 | -38 | — | — | — | — | — | — | |
| Consolidated Net Income | 266 | 251 | 81 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 277 | 262 | 88 | — | — | — | — | — | — | |
| Net Income | 266 | 251 | 81 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.55 | 0.55 | 0.20 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.55 | 0.55 | 0.20 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.54 | 0.54 | 0.19 | — | — | — | — | — | — | |
| EBITDA | 2,497 | 2,239 | 1,937 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 169.80 | 143.30 | 309.95 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.87 | 6.03 | 4.93 | — | — | — | — | — | — | |
| Gross Margin | -2.59 | -5.90 | 42.59 | — | — | — | — | — | — | |
| Operating Margin | 12.95 | 14.18 | 13.83 | — | — | — | — | — | — | |
| Net Margin | 4.13 | 4.30 | 1.65 | — | — | — | — | — | — | |
| Shares Outstanding | 483 | 455 | 412 | — | — | — | — | — | — | |
| Market Capitalization | 44,286 | 35,208 | 24,263 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| EMBLER MICHAEL J | Director | Jun 03 '26 | Buy | 78.81 | 2,500 | 197,025 | 19,202 | Jun 05 |
| RAKOWICH WALTER C | Director | May 14 '26 | Sale | 90.20 | 1,152 | 103,915 | 28,349 | May 15 |
| Roberts Carey S. | EVP and GC | Feb 11 '26 | Sale | 85.00 | 35,532 | 3,020,117 | 72,755 | Feb 13 |
| CAFARO DEBRA A | Chairman and CEO | Feb 06 '26 | Option Exercise | 73.71 | 10,322 | 760,835 | 1,124,356 | Feb 10 |
| CAFARO DEBRA A | Chairman and CEO | Feb 06 '26 | Sale | 82.23 | 10,322 | 848,751 | 1,114,034 | Feb 10 |
| CAFARO DEBRA A | Chairman and CEO | Feb 02 '26 | Sale | 77.66 | 10,322 | 801,605 | 1,114,034 | Feb 03 |
| CAFARO DEBRA A | Chairman and CEO | Feb 02 '26 | Option Exercise | 73.71 | 10,322 | 760,835 | 1,124,356 | Feb 03 |
| CAFARO DEBRA A | Chairman and CEO | Jan 02 '26 | Option Exercise | 73.71 | 10,322 | 760,835 | 1,156,017 | Jan 06 |
| CAFARO DEBRA A | Chairman and CEO | Jan 02 '26 | Sale | 77.26 | 10,322 | 797,475 | 1,145,695 | Jan 06 |
| Probst Robert F | EVP and CFO | Jan 02 '26 | Sale | 77.25 | 29,930 | 2,312,188 | 138,434 | Jan 06 |
| CAFARO DEBRA A | Chairman and CEO | Dec 01 '25 | Option Exercise | 73.71 | 10,322 | 760,835 | 1,156,017 | Dec 03 |
| CAFARO DEBRA A | Chairman and CEO | Dec 01 '25 | Sale | 80.55 | 10,322 | 831,419 | 1,145,695 | Dec 03 |
| Bulgarelli Peter J. | EVP OM&R-Ventas/Pres&CEO-LHS | Nov 19 '25 | Sale | 80.08 | 2,229 | 178,504 | 106,488 | Nov 20 |
| Bulgarelli Peter J. | EVP OM&R-Ventas/Pres&CEO-LHS | Nov 18 '25 | Sale | 80.01 | 2,771 | 221,701 | 108,717 | Nov 20 |
| CAFARO DEBRA A | Chairman and CEO | Nov 17 '25 | Option Exercise | 73.71 | 41,294 | 3,043,781 | 1,186,989 | Nov 19 |